Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep;57(5):415-29.
doi: 10.1016/j.survophthal.2012.01.007.

Corneal neovascularization: an anti-VEGF therapy review

Jin-Hong Chang  1 , Nitin K Garg, Elisa Lunde, Kyu-Yeon Han, Sandeep Jain, Dimitri T Azar
Affiliations
Review

Corneal neovascularization: an anti-VEGF therapy review

Jin-Hong Chang et al. Surv Ophthalmol. 2012 Sep.

Abstract

Corneal neovascularization is a serious condition that can lead to a profound decline in vision. The abnormal vessels block light, cause corneal scarring, compromise visual acuity, and may lead to inflammation and edema. Corneal neovascularization occurs when the balance between angiogenic and antiangiogenic factors is tipped toward angiogenic molecules. Vascular endothelial growth factor (VEGF), one of the most important mediators of angiogenesis, is upregulated during neovascularization. In fact, anti-VEGF agents have efficacy in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and other neovascular diseases. These same agents have great potential for the treatment of corneal neovascularization. We review some of the most promising anti-VEGF therapies, including bevacizumab, VEGF trap, siRNA, and tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

VII. Disclosure

The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. Publication for this article was supported by National Institute of Health (Bethesda, MD) grants EY021886 (JHC), EY10101 (DTA), EY01792 (DTA) and an unrestricted grant from Research to Prevent Blindness, New York, NY.

References

    1. Ahmed A, Berati H, Nalan A, et al. Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Experiment Ophthalmol. 2009;37:730–6. - PubMed
    1. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18–22. - PubMed
    1. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993–7. - PMC - PubMed
    1. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–72. - PubMed
    1. Avila MP, Farah ME, Santos A, et al. Three-year safety and visual acuity results of epimacular 90strontium/90yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina. 2011;32(1):10–8. - PubMed

Publication types

MeSH terms